Positive opinion for Iluvien in France

Article

The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

The intravitreal implant, developed by Alimera Sciences for the treatment of diabetic macular oedmea (DME), has completed two Phase III clinical trials and demonstrates an improvement in best-corrected visual acuity (BVCA) and an increase in ETDRS eye chart letters.

Professor Gisele Soubrane, clinical investigator for Iluvien, commented, “The Iluvien implant features a sustained-release of the active pharmaceutical agent for up to 36 months, which is in balance with the insidious progression of macular oedema due to long-term diabetes mellitus. The clinical results of the trials were significant; Iluvien provides a new, effective mode for achieving vision improvement."

Dan Myers, Alimera's president and chief executive officer, stated, "We are pleased to receive the CT's positive opinion for reimbursement of Iluvien. We believe this opinion will help us in our discussions with the CEPS pricing committee as we work to make Iluvien available to those suffering from chronic DME in France."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.